PTC Therapeutics Overview
Valuation check: PTCT's ROE is 23.21%, above the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow23.21%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, PTCT shows a ROE of 23.21%. That is above the Healthcare sector average of 20.77%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 20.77%. PTC Therapeutics is at 23.21%, which is higher that average. That is roughly 11.8% above the sector mean. Use the comparison chart on this page to see how PTCT stacks up against individual peers as well.
Check the historical chart to see whether PTCT's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare PTC Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has PTC Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 23.21%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 20.77%, while PTCT is at 23.21%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
